Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.
Identifieur interne : 004978 ( Main/Merge ); précédent : 004977; suivant : 004979Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.
Auteurs : Jonathan P. Wong [Canada] ; Les P. Nagata ; Mary E. Christopher ; Andres M. Salazar ; Roderic M K. DaleSource :
- Vaccine [ 0264-410X ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Carboxyméthylcellulose de sodium (administration et posologie), Carboxyméthylcellulose de sodium (analogues et dérivés), Carboxyméthylcellulose de sodium (pharmacologie), Encéphalomyélite équine (), Grippe humaine (), Humains, Ilots CpG, Infections de l'appareil respiratoire (), Liposomes, Maladies virales (), Oligodésoxyribonucléotides (administration et posologie), Oligodésoxyribonucléotides (pharmacologie), Poly I-C (administration et posologie), Poly I-C (pharmacologie), Polylysine (administration et posologie), Polylysine (analogues et dérivés), Polylysine (pharmacologie), Souris, Virus de l'encéphalite équine de l'Ouest, Virus de la grippe A.
- MESH :
- administration et posologie : Carboxyméthylcellulose de sodium, Oligodésoxyribonucléotides, Poly I-C, Polylysine.
- analogues et dérivés : Carboxyméthylcellulose de sodium, Polylysine.
- pharmacologie : Carboxyméthylcellulose de sodium, Oligodésoxyribonucléotides, Poly I-C, Polylysine.
- Animaux, Encéphalomyélite équine, Grippe humaine, Humains, Ilots CpG, Infections de l'appareil respiratoire, Liposomes, Maladies virales, Souris, Virus de l'encéphalite équine de l'Ouest, Virus de la grippe A.
English descriptors
- KwdEn :
- Animals, Carboxymethylcellulose Sodium (administration & dosage), Carboxymethylcellulose Sodium (analogs & derivatives), Carboxymethylcellulose Sodium (pharmacology), CpG Islands, Encephalitis Virus, Western Equine, Encephalomyelitis, Equine (prevention & control), Humans, Influenza A virus, Influenza, Human (prevention & control), Liposomes, Mice, Oligodeoxyribonucleotides (administration & dosage), Oligodeoxyribonucleotides (pharmacology), Poly I-C (administration & dosage), Poly I-C (pharmacology), Polylysine (administration & dosage), Polylysine (analogs & derivatives), Polylysine (pharmacology), Respiratory Tract Infections (prevention & control), Virus Diseases (prevention & control).
- MESH :
- chemical , administration & dosage : Carboxymethylcellulose Sodium, Oligodeoxyribonucleotides, Poly I-C, Polylysine.
- chemical , analogs & derivatives : Carboxymethylcellulose Sodium, Polylysine.
- chemical , pharmacology : Carboxymethylcellulose Sodium, Oligodeoxyribonucleotides, Poly I-C, Polylysine.
- prevention & control : Encephalomyelitis, Equine, Influenza, Human, Respiratory Tract Infections, Virus Diseases.
- Animals, CpG Islands, Encephalitis Virus, Western Equine, Humans, Influenza A virus, Liposomes, Mice.
Abstract
Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.
DOI: 10.1016/j.vaccine.2005.01.037
PubMed: 15755608
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002855
- to stream PubMed, to step Curation: 002855
- to stream PubMed, to step Checkpoint: 002570
- to stream Ncbi, to step Merge: 000E19
- to stream Ncbi, to step Curation: 000E19
- to stream Ncbi, to step Checkpoint: 000E19
Links to Exploration step
pubmed:15755608Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.</title><author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P" last="Wong">Jonathan P. Wong</name><affiliation wicri:level="1"><nlm:affiliation>Defence R&D Canada--Suffield, Alberta, Canada. jonathan.wong@drdc-rddc.gc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Defence R&D Canada--Suffield, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P" last="Nagata">Les P. Nagata</name></author><author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E" last="Christopher">Mary E. Christopher</name></author><author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M" last="Salazar">Andres M. Salazar</name></author><author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M K" last="Dale">Roderic M K. Dale</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15755608</idno><idno type="pmid">15755608</idno><idno type="doi">10.1016/j.vaccine.2005.01.037</idno><idno type="wicri:Area/PubMed/Corpus">002855</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002855</idno><idno type="wicri:Area/PubMed/Curation">002855</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002855</idno><idno type="wicri:Area/PubMed/Checkpoint">002570</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002570</idno><idno type="wicri:Area/Ncbi/Merge">000E19</idno><idno type="wicri:Area/Ncbi/Curation">000E19</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E19</idno><idno type="wicri:doubleKey">0264-410X:2005:Wong J:prophylaxis:of:acute</idno><idno type="wicri:Area/Main/Merge">004978</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.</title><author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P" last="Wong">Jonathan P. Wong</name><affiliation wicri:level="1"><nlm:affiliation>Defence R&D Canada--Suffield, Alberta, Canada. jonathan.wong@drdc-rddc.gc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Defence R&D Canada--Suffield, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P" last="Nagata">Les P. Nagata</name></author><author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E" last="Christopher">Mary E. Christopher</name></author><author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M" last="Salazar">Andres M. Salazar</name></author><author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M K" last="Dale">Roderic M K. Dale</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Carboxymethylcellulose Sodium (administration & dosage)</term><term>Carboxymethylcellulose Sodium (analogs & derivatives)</term><term>Carboxymethylcellulose Sodium (pharmacology)</term><term>CpG Islands</term><term>Encephalitis Virus, Western Equine</term><term>Encephalomyelitis, Equine (prevention & control)</term><term>Humans</term><term>Influenza A virus</term><term>Influenza, Human (prevention & control)</term><term>Liposomes</term><term>Mice</term><term>Oligodeoxyribonucleotides (administration & dosage)</term><term>Oligodeoxyribonucleotides (pharmacology)</term><term>Poly I-C (administration & dosage)</term><term>Poly I-C (pharmacology)</term><term>Polylysine (administration & dosage)</term><term>Polylysine (analogs & derivatives)</term><term>Polylysine (pharmacology)</term><term>Respiratory Tract Infections (prevention & control)</term><term>Virus Diseases (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Carboxyméthylcellulose de sodium (administration et posologie)</term><term>Carboxyméthylcellulose de sodium (analogues et dérivés)</term><term>Carboxyméthylcellulose de sodium (pharmacologie)</term><term>Encéphalomyélite équine ()</term><term>Grippe humaine ()</term><term>Humains</term><term>Ilots CpG</term><term>Infections de l'appareil respiratoire ()</term><term>Liposomes</term><term>Maladies virales ()</term><term>Oligodésoxyribonucléotides (administration et posologie)</term><term>Oligodésoxyribonucléotides (pharmacologie)</term><term>Poly I-C (administration et posologie)</term><term>Poly I-C (pharmacologie)</term><term>Polylysine (administration et posologie)</term><term>Polylysine (analogues et dérivés)</term><term>Polylysine (pharmacologie)</term><term>Souris</term><term>Virus de l'encéphalite équine de l'Ouest</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboxymethylcellulose Sodium</term><term>Oligodeoxyribonucleotides</term><term>Poly I-C</term><term>Polylysine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Carboxymethylcellulose Sodium</term><term>Polylysine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Carboxymethylcellulose Sodium</term><term>Oligodeoxyribonucleotides</term><term>Poly I-C</term><term>Polylysine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term><term>Oligodésoxyribonucléotides</term><term>Poly I-C</term><term>Polylysine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term><term>Polylysine</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Carboxyméthylcellulose de sodium</term><term>Oligodésoxyribonucléotides</term><term>Poly I-C</term><term>Polylysine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Encephalomyelitis, Equine</term><term>Influenza, Human</term><term>Respiratory Tract Infections</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CpG Islands</term><term>Encephalitis Virus, Western Equine</term><term>Humans</term><term>Influenza A virus</term><term>Liposomes</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Encéphalomyélite équine</term><term>Grippe humaine</term><term>Humains</term><term>Ilots CpG</term><term>Infections de l'appareil respiratoire</term><term>Liposomes</term><term>Maladies virales</term><term>Souris</term><term>Virus de l'encéphalite équine de l'Ouest</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004978 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004978 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:15755608
|texte= Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:15755608" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |